Cargando…

Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases

BACKGROUND: Population-based analysis for the liver metastases of small bowel cancer is currently lacking. This study aimed to analyze the frequency, prognosis and treatment modalities for newly diagnosed small bowel cancer patients with liver metastases. METHODS: Patients with small bowel cancer di...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xiaorong, Wang, Lifu, Xing, Yongjun, Song, Chengjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558693/
https://www.ncbi.nlm.nih.gov/pubmed/33059631
http://dx.doi.org/10.1186/s12876-020-01487-6
_version_ 1783594696692465664
author Ye, Xiaorong
Wang, Lifu
Xing, Yongjun
Song, Chengjun
author_facet Ye, Xiaorong
Wang, Lifu
Xing, Yongjun
Song, Chengjun
author_sort Ye, Xiaorong
collection PubMed
description BACKGROUND: Population-based analysis for the liver metastases of small bowel cancer is currently lacking. This study aimed to analyze the frequency, prognosis and treatment modalities for newly diagnosed small bowel cancer patients with liver metastases. METHODS: Patients with small bowel cancer diagnosed from 2010 to 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Binary logistic regression analysis was performed to determine predictors for the presence of liver metastases at diagnosis. Kaplan–Meier method and Cox regression analyses were performed for survival analyses. RESULTS: A total of 1461 small bowel cancer patients with liver metastases at initial diagnosis were identified, representing 16.5% of the entire set and 63.9% of the subset with metastatic disease to any distant site. Primary tumor with poorer histological type, larger tumor size, later N staging, more extrahepatic metastatic sites, and tumor on lower part of small intestine had increased propensity of developing liver metastases. The combined diagnostic model exhibited acceptable diagnostic efficiency with AUC value equal to 0.749. Patients with liver metastases had significant poorer survival (P < 0.001) than those without liver metastases. In addition, combination of surgery and chemotherapy (HR = 0.27, P < 0.001) conferred the optimal survival for patients with adenocarcinoma, while the optimal treatment options for NEC and GIST seemed to be surgery alone (HR = 0.24, P < 0.001) and chemotherapy alone (HR = 0.08, P = 0.022), respectively. CONCLUSIONS: The combined predictor had a good ability to predict the presence of liver metastases. In addition, those patients with different histologic types should be treated with distinct therapeutic strategy for obtaining optimal survival.
format Online
Article
Text
id pubmed-7558693
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75586932020-10-15 Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases Ye, Xiaorong Wang, Lifu Xing, Yongjun Song, Chengjun BMC Gastroenterol Research Article BACKGROUND: Population-based analysis for the liver metastases of small bowel cancer is currently lacking. This study aimed to analyze the frequency, prognosis and treatment modalities for newly diagnosed small bowel cancer patients with liver metastases. METHODS: Patients with small bowel cancer diagnosed from 2010 to 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Binary logistic regression analysis was performed to determine predictors for the presence of liver metastases at diagnosis. Kaplan–Meier method and Cox regression analyses were performed for survival analyses. RESULTS: A total of 1461 small bowel cancer patients with liver metastases at initial diagnosis were identified, representing 16.5% of the entire set and 63.9% of the subset with metastatic disease to any distant site. Primary tumor with poorer histological type, larger tumor size, later N staging, more extrahepatic metastatic sites, and tumor on lower part of small intestine had increased propensity of developing liver metastases. The combined diagnostic model exhibited acceptable diagnostic efficiency with AUC value equal to 0.749. Patients with liver metastases had significant poorer survival (P < 0.001) than those without liver metastases. In addition, combination of surgery and chemotherapy (HR = 0.27, P < 0.001) conferred the optimal survival for patients with adenocarcinoma, while the optimal treatment options for NEC and GIST seemed to be surgery alone (HR = 0.24, P < 0.001) and chemotherapy alone (HR = 0.08, P = 0.022), respectively. CONCLUSIONS: The combined predictor had a good ability to predict the presence of liver metastases. In addition, those patients with different histologic types should be treated with distinct therapeutic strategy for obtaining optimal survival. BioMed Central 2020-10-15 /pmc/articles/PMC7558693/ /pubmed/33059631 http://dx.doi.org/10.1186/s12876-020-01487-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ye, Xiaorong
Wang, Lifu
Xing, Yongjun
Song, Chengjun
Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases
title Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases
title_full Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases
title_fullStr Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases
title_full_unstemmed Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases
title_short Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases
title_sort frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558693/
https://www.ncbi.nlm.nih.gov/pubmed/33059631
http://dx.doi.org/10.1186/s12876-020-01487-6
work_keys_str_mv AT yexiaorong frequencyprognosisandtreatmentmodalitiesofnewlydiagnosedsmallbowelcancerwithlivermetastases
AT wanglifu frequencyprognosisandtreatmentmodalitiesofnewlydiagnosedsmallbowelcancerwithlivermetastases
AT xingyongjun frequencyprognosisandtreatmentmodalitiesofnewlydiagnosedsmallbowelcancerwithlivermetastases
AT songchengjun frequencyprognosisandtreatmentmodalitiesofnewlydiagnosedsmallbowelcancerwithlivermetastases